Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 2351 - 2375 of 15187 in total

Fosphenytoin

Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
Approved
Investigational
Matched Iupac: … [(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methoxy]phosphonic acid …
Matched Description: … channels, and therefore limit repetitive firing of action potentials. ... Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium …
Matched Categories: … Phenytoin and Prodrugs …

Belatacept

Belatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it...
Approved
Investigational
Matched Description: … domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and ... Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Axicabtagene ciloleucel

Axicabtagene ciloleucel is an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. The drug has a unique mechanism of action, as it utilizes the patient's own T cells, which play a central role in immune response to cancer. Once T-cells are collected from the patient, they are genetically engineered to express...
Approved
Matched Description: … It is marketed under the brand name Yescarta and is used to treat large B-cell lymphomas and follicular ... kill cancer cells, and are infused back into the patient. ... collected from the patient, they are genetically engineered to express anti-CD19 CARs that recognize and …
Matched Categories: … Antineoplastic cell and gene therapy ... Antineoplastic and Immunomodulating Agents …

Deucravacitinib

Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. Unlike other Janus kinase 1/2/3 inhibitors that bind to the conserved active domain of these non-receptor tyrosine kinases, deucravacitinib binds to the regulatory domain of TYK2 with high selectivity to this therapeutic target.[A246938, A246943] This selectivity towards TYK2 may...
Approved
Investigational
Matched Description: … triglyceride levels and liver and kidney dysfunction. ... [L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines ... nonselective JAK inhibitors are associated with a range of adverse effects such as altered cholesterol and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Vespula squamosa venom protein

Vespula squamosa venom protein is an extract of Vespula squamosa venom. Vespula squamosa venom protein is used in allergenic testing.
Approved
Matched Categories: … Bee and Wasp Venom …

Sotatercept

Sotatercept is an activin signalling inhibitor. It is a homodimeric recombinant fusion protein consisting of the extracellular domain of the human activin receptor type IIA (ActRIIA) linked to the human IgG1 Fc domain. On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension...
Approved
Investigational
Matched Description: … [L50361] Sotatercept works to resolve the imbalance in activin–growth differentiation factor and BMP …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Efbemalenograstim alfa

Efbemalenograstim alfa is a long-acting recombinant fusion protein of granulocyte-colony stimulating factor (G-CSF) due to the addition of the Fc portion of human IgG2, allowing for once-per-cycle administration.[L48852,A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and eventually neutrophils, the administration of recombinant G-CSF like efbemalenograstim...
Approved
Matched Description: … GC-627-05 in the US and Europe respectively. ... thus reducing the severity and duration of neutropenia. ... A262167] As endogenous G-CSF mediates the differentiation of hematopoietic stem cells into granulocytes and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Protamine sulfate

Since it's earliest discovery in salmon rine sperm heads in the late 1800's to its formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps the only viable option for reversing the anticoagulant effect of heparin use for over 77 years [A174778,...
Approved
Matched Description: … kidney tissue damage, and anaphylactic reaction, amongst others [A174778, L5371]. ... reversal predominantly via the formation of an inactive complex between the anionic nature of heparin and ... potential range in reversing all parenteral anticoagulants are sometimes considered high and limited …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Lonafarnib

Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384,...
Approved
Investigational
Matched Description: … treatment for HGPS and other related progeroid laminopathies. ... [A224379, A224414, A224419, L23414] Merck originally developed Lonafarnib and subsequently licensed ... [L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved …
Matched Categories: … Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Alefacept

Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.
Approved
Investigational
Withdrawn
Matched Description: … CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Caplacizumab

Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy...
Approved
Investigational
Matched Description: … Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and ... approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Blood and Blood Forming Organs …

Ambroxol

Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Lasolvan or Mucoangin. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the...
Approved
Investigational
Matched Description: … in providing protection against infection and irritating agents. ... It stimulates synthesis and release of surfactant by type II pneumocytes. ... The substance is a mucoactive drug with several properties including secretolytic and secretomotoric …
Matched Categories: … Cough and Cold Preparations ... clenbuterol and ambroxol …

Keyhole limpet hemocyanin

Keyhole limpet hemocyanin is an immune modulator, given as a vaccine to help the body respond to cancer. A natural protein isolated from the marine mollusc keyhole limpet. Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such...
Approved
Investigational
Matched Description: … hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and …
Matched Categories: … Amino Acids, Peptides, and Proteins …

Casimersen

Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive impairment of ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is...
Approved
Investigational
Matched Description: … [A218186, L32118] In this manner, PMOs are much less susceptible to endo- and exonucleases and exhibit ... cardiac function and is invariably fatal. ... lack of functional dystrophin protein, which leads to progressive impairment of ambulatory, pulmonary, and …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …

Doxapram

A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)
Approved
Vet approved

Rucaparib

Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer...
Approved
Investigational
Matched Description: … Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. ... [L42185] It is currently used to treat recurrent ovarian and prostate cancer in adults. ... [A18745] Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Trabectedin

Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair...
Approved
Investigational
Matched Description: … and ovarian cancer. ... and DNA repair machinery. ... Both the European Commission and the U.S. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Inotuzumab ozogamicin

Inotuzumab ozogamicin is an antibody-drug conjugate consisting of a humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide. The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly releases N-acetyl-gamma-calicheamicin dimethylhydrazide, which produces cytotoxic effects. Inotuzumab ozogamicin was first...
Approved
Investigational
Matched Description: … [A20352] The antibody portion of the drug binds to CD22 receptors expressed on leukemic B cells and intracellularly …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Amsacrine

Aminoacridine derivative that is a potent intercalating antineoplastic agent. It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors. It is frequently used in combination with other antineoplastic agents in chemotherapy protocols. It produces consistent but acceptable myelosuppression...
Approved
Investigational
Matched Description: … It produces consistent but acceptable myelosuppression and cardiotoxic effects. ... It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in …
Matched Categories: … Indicators and Reagents ... Antineoplastic and Immunomodulating Agents …

Choline C 11

Choline C 11 is a marker for cellular proliferation as its main molecule is a precursor for the biosynthesis of phospholipids which are essential components of all cell membranes. It was developed by MCPRF and FDA first approved in September 2012.
Approved
Investigational
Matched Description: … [A32041] It was developed by MCPRF and FDA first approved in September 2012. …

Oliceridine

Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for...
Approved
Investigational
Matched Description: … Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal ... beneficial analgesic effects of opioids are coupled with severe adverse effects such as constipation and ... G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and …
Matched Categories: … Sulfur Compounds …

Myrrh

Extractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, obtained from Commiphora abyssinica, Burseraceae.
Approved
Matched Description: … Extractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential …

Metergoline

Metergoline is an ergot-derived psychoactive drug that acts as a ligand for serotonin and dopamine receptors. Metergoline is an antagonist at various 5-HT receptor subtypes at a relatively low concentration and agonist at dopamine receptors. Its use has been studied in various clinical settings such as a treatment for seasonal...
Approved
Matched Description: … Metergoline is an antagonist at various 5-HT receptor subtypes at a relatively low concentration and ... Metergoline is an ergot-derived psychoactive drug that acts as a ligand for serotonin and dopamine receptors ... due to its inhibitory effect on prolactin release,[A27182] premenstrual dysphoric disorder in women and …
Matched Categories: … Ergot Alkaloids and Derivatives ... Genito Urinary System and Sex Hormones …

Vibegron

Vibegron is a potent, selective beta-3 adrenergic receptor (β3) agonist that relaxes the detrusor smooth muscle of the bladder, thereby increasing bladder capacity. Vibegron was first approved in Japan in September 2018 for the treatment of overactive bladder, a condition associated with distressing symptoms of urge urinary incontinence, urgency, and...
Approved
Investigational
Matched Description: … urinary frequency, and reduced quality of life of patients. ... bladder,[A226050] a condition associated with distressing symptoms of urge urinary incontinence, urgency, and …
Matched Categories: … Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …

Pirfenidone

Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate...
Approved
Investigational
Matched Description: … [A251370] It is an antifibrotic agent with anti-inflammatory and antioxidant properties [A251370] that ... fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 2351 - 2375 of 15187 in total